Elanco Animal Health Incorporated $ELAN Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. trimmed its Elanco stake by 1.1% in Q4, selling 526,977 shares and ending the period with 48,059,731 shares (9.67% ownership) worth about $1.088 billion.
• Q4 results and guidance: Elanco beat expectations with $0.13 EPS (vs. $0.11) and $1.14B revenue (up 12.2%), and set Q1 2026 guidance of $0.330–0.36 and FY 2026 guidance of $1.00–1.06 EPS.
• Market view and metrics: The stock carries a consensus "Moderate Buy" with an average target of $27.90, trades near $22.54 (52‑week $9.42–$27.72), has a market cap around $11.2B, and about 97% of shares are held by institutional investors.

Vanguard Group Inc. reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 48,059,731 shares of the company's stock after selling 526,977 shares during the quarter. Vanguard Group Inc. owned 9.67% of Elanco Animal Health worth $1,087,592,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Legacy Capital Group California Inc. increased its stake in Elanco Animal Health by 3.1% during the 4th quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company's stock worth $475,000 after buying an additional 632 shares during the period. AlphaQuest LLC increased its stake in Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company's stock worth $120,000 after buying an additional 718 shares during the period. Jones Financial Companies Lllp increased its stake in Elanco Animal Health by 15.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company's stock worth $119,000 after buying an additional 798 shares during the period. US Bancorp DE increased its stake in Elanco Animal Health by 1.9% during the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company's stock worth $882,000 after buying an additional 824 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock worth $42,000 after buying an additional 900 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Up 0.8%

Shares of NYSE:ELAN opened at $22.54 on Friday. Elanco Animal Health Incorporated has a 52 week low of $9.42 and a 52 week high of $27.72. The company's 50 day moving average is $23.86 and its two-hundred day moving average is $23.23. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The company has a market cap of $11.21 billion, a PE ratio of -46.96, a P/E/G ratio of 2.85 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm posted $0.14 EPS. The company's quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities analysts predict that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent research reports. Weiss Ratings raised shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research note on Monday. UBS Group reaffirmed a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Piper Sandler raised shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. KeyCorp upped their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley increased their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $27.90.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.